MUC16 and ovarian cancer: An antibody drug conjugate (DMUC5754A) uses an alternative MUC16 antibody directed against the repeat region conjugated to a drug (monomethyl auristatin E; MMAE) that disrupts microtubules, and was found to have an acceptable safety profile and some evidence of anti-tumour activity in a Phase I clinical trial for ovarian cancer patients with platinum resistance [365].